While finding the optimal PD-L1 expression cut-off may be difficult, another difficulty arises from the fact that it may not be possible to establish a single standardised threshold suitable for all cancer types; a study analysing all primary studies associated with FDA approvals of ICIs found that the PD-L1 threshold varied not only between cancers but also within cancer types [22]. This evidence concerns the gene CD274 and cancer.